$141.00
6.74[5.02%]
Last update: 10:44AM Get Real Time Here
Quest Diagnostics
(NYSE:DGX)Quest Diagnostics Stock (NYSE:DGX), Analyst Ratings, Price Targets, Predictions
Quest Diagnostics Inc has a consensus price target of $150.21, established from looking at the 56 latest analyst ratings. The last 3 analyst ratings were released from Barclays, Citigroup, and UBS on April 25, 2024, April 24, 2024, and April 24, 2024. With an average price target of $145 between Barclays, Citigroup, and UBS, there's an implied 8.00% upside for Quest Diagnostics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Barclays
Citigroup
UBS
Truist Securities
Mizuho
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Quest Diagnostics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/25/2024 | DGX | Buy Now | Quest Diagnostics | $134.26 | 7.25% | Barclays | Stephanie Davis | $138 → $144 | Maintains | Equal-Weight | Get Alert |
| 04/24/2024 | DGX | Buy Now | Quest Diagnostics | $134.26 | 8% | Citigroup | Patrick Donnelly | $135 → $145 | Maintains | Neutral | Get Alert |
| 04/24/2024 | DGX | Buy Now | Quest Diagnostics | $134.26 | 8.74% | UBS | Kevin Caliendo | $139 → $146 | Maintains | Neutral | Get Alert |
| 04/24/2024 | DGX | Buy Now | Quest Diagnostics | $134.26 | 11.72% | Truist Securities | David Macdonald | $145 → $150 | Maintains | Hold | Get Alert |
| 04/24/2024 | DGX | Buy Now | Quest Diagnostics | $134.26 | 15.45% | Mizuho | Ann Hynes | $150 → $155 | Maintains | Buy | Get Alert |
| 03/20/2024 | DGX | Buy Now | Quest Diagnostics | $134.26 | 8% | Truist Securities | David Macdonald | → $145 | Reiterates | Hold → Hold | Get Alert |
| 02/26/2024 | DGX | Buy Now | Quest Diagnostics | $134.26 | 0.55% | Leerink Partners | Michael Cherny | → $135 | Initiates | → Market Perform | Get Alert |
| 02/07/2024 | DGX | Buy Now | Quest Diagnostics | $134.26 | 15.45% | Jefferies | Brian Tanquilut | $140 → $155 | Upgrade | Hold → Buy | Get Alert |
| 02/02/2024 | DGX | Buy Now | Quest Diagnostics | $134.26 | 8% | Truist Securities | David Macdonald | $150 → $145 | Maintains | Hold | Get Alert |
| 12/20/2023 | DGX | Buy Now | Quest Diagnostics | $134.26 | 11.72% | Truist Securities | David Macdonald | $145 → $150 | Maintains | Hold | Get Alert |
| 12/12/2023 | DGX | Buy Now | Quest Diagnostics | $134.26 | 19.17% | B of A Securities | Derik De Bruin | $140 → $160 | Upgrade | Neutral → Buy | Get Alert |
| 12/11/2023 | DGX | Buy Now | Quest Diagnostics | $134.26 | 8% | Citigroup | Patrick Donnelly | $130 → $145 | Maintains | Neutral | Get Alert |
| 12/07/2023 | DGX | Buy Now | Quest Diagnostics | $134.26 | 2.04% | UBS | Kevin Caliendo | $135 → $137 | Maintains | Neutral | Get Alert |
| 11/17/2023 | DGX | Buy Now | Quest Diagnostics | $134.26 | 10.98% | JP Morgan | John Stansel | $148 → $149 | Maintains | Neutral | Get Alert |
| 11/06/2023 | DGX | Buy Now | Quest Diagnostics | $134.26 | 4.28% | Piper Sandler | David Westenberg | $130 → $140 | Maintains | Neutral | Get Alert |
| 10/25/2023 | DGX | Buy Now | Quest Diagnostics | $134.26 | -3.17% | Citigroup | Patrick Donnelly | $142 → $130 | Maintains | Neutral | Get Alert |
| 10/16/2023 | DGX | Buy Now | Quest Diagnostics | $134.26 | -3.17% | Piper Sandler | David Westenberg | $145 → $130 | Maintains | Neutral | Get Alert |
| 08/03/2023 | DGX | Buy Now | Quest Diagnostics | $134.26 | 8% | Morgan Stanley | Ricky Goldwasser | $145 → $145 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/29/2023 | DGX | Buy Now | Quest Diagnostics | $134.26 | 8% | Piper Sandler | David Westenberg | → $145 | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for Quest Diagnostics (DGX)?
The latest price target for Quest Diagnostics (NYSE: DGX) was reported by Barclays on April 25, 2024. The analyst firm set a price target for $144.00 expecting DGX to rise to within 12 months (a possible 2.13% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Quest Diagnostics (DGX)?
The latest analyst rating for Quest Diagnostics (NYSE: DGX) was provided by Barclays, and Quest Diagnostics maintained their equal-weight rating.
When was the last upgrade for Quest Diagnostics (DGX)?
The last upgrade for Quest Diagnostics Inc happened on February 7, 2024 when Jefferies raised their price target to $155. Jefferies previously had a hold for Quest Diagnostics Inc.
When was the last downgrade for Quest Diagnostics (DGX)?
The last downgrade for Quest Diagnostics Inc happened on May 2, 2023 when B of A Securities changed their price target from $166 to $148 for Quest Diagnostics Inc.
When is the next analyst rating going to be posted or updated for Quest Diagnostics (DGX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Quest Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Quest Diagnostics was filed on April 25, 2024 so you should expect the next rating to be made available sometime around April 25, 2025.
Is the Analyst Rating Quest Diagnostics (DGX) correct?
While ratings are subjective and will change, the latest Quest Diagnostics (DGX) rating was a maintained with a price target of $138.00 to $144.00. The current price Quest Diagnostics (DGX) is trading at is $141.00, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.